Cashu
Vanda Pharmaceuticals Submits BLA for Imsidolimab, Targeting Rare Skin Condition GPP
3 days ago
Stocks
Health Care
vnda
Vanda Pharmaceuticals
NASDAQ: VNDA
+0.08 (+1.27%)
6.755
USD
At close at Dec 19, 21:38 UTC
Overview
Loading chart...
Key Stats
Market Cap
398.85M
Dividend Yield
0.00%
P/E Ratio
-4.74
EPS
-0.33
Revenue
198.77M
Avg. Volume
1.59M
About
What does VNDA do?
Vanda Pharmaceuticals, headquartered in Washington, D.C., develops therapies for unmet medical needs and has three commercial products, including HETLIOZ and Fanapt. The company also has multiple drugs in development.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.